Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404524 | 0.83 | CYP1A2 (0.57) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL29404615 | 0.83 | CYP1A2 (0.57) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| Ammonia Solution, Strong SCHEMBL28514949 | 0.82 | CYP1A2 (0.55) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL1564322 | 0.80 | CYP1A2 (0.53) | CYP1A2CYP2A6KDM4ETSHRGPR3 | |
| SCHEMBL2171256 | 0.80 | CYP1A2 (0.53) | CYP1A2CYP2A6ALDH1A1UHRF1KDM4E | |
| SCHEMBL23935936 | 0.80 | PDPK1 (0.53) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL12330380 | 0.80 | CYP1A2 (0.53) | CYP1A2CYP2A6UHRF1KDM4EGPR3 | |
| SCHEMBL18379303 | 0.80 | CYP1A2 (0.47) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL19044152 | 0.80 | CYP1A2 (0.47) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL1348625 | 0.80 | CYP1A2 (0.53) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3125949-B1 | DENDRONIZED METALLIC OXIDE NANOPARTICLES, A PROCESS FOR PREPARING THE SAME AND THEIR USES | CENTRE NAT RECH SCIENT (FR) | 2023-11-08 | — | — | EP | disclosed |
| EP-1857521-B2 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | MITSUBISHI CHEM CORP (JP) | 2021-12-22 | — | — | EP | disclosed |
| US-9865820-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2018-01-09 | — | — | US | disclosed |
| US-9640769-B2 | Organic electric field light emitting element and production therefor | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-05-02 | — | — | US | disclosed |
| US-9640769-B2 | Organic electric field light emitting element and production therefor | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| EP-2439204-B1 | HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER | NISSAN CHEMICAL IND LTD (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9527828-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9527828-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20160351817-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-12-01 | — | — | US | disclosed |
| US-20090192154-A1 | SULTAM DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | SMITHKLINE BEECHAM PLC. (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | SMITHKLINE BEECHAM PLC. (GB) | 2009-06-25 | — | — | US | disclosed |
| US-7514562-B2 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| US-7514562-B2 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| EP-2036902-A2 | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | Glaxo Group Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| US-20090066223-A1 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-1857521-A1 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | Mitsubishi Chemical Corporation (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007067444-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | TRPV1, OPRL1, UTS2R | CYP1A2 2228/4885CYP2A6 1486/4885ALDH1A1 2656/4885 |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | CYP1A2 4427/4885CYP2A6 3831/4885ALDH1A1 2149/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | CYP1A2 3219/4885CYP2A6 3698/4885ALDH1A1 4226/4885 |
| US-20090192154-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, ADAMTS1 | CYP1A2 1655/4885CYP2A6 1111/4885ALDH1A1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.